Insider Selling: Medifast (NYSE:MED) Director Sells $114,349.10 in Stock

Posted by Geri Gentry on Oct 3rd, 2026

Medifast Inc (NYSE:MED – Get Free Report) Director Daniel Chard sold 9,545 shares of Medifast stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $11.98, for a total transaction of $114,349.10. Following the completion of the sale, the director owned 140,153 shares in the company, valued at approximately $1,679,032.94. This trade represents a 6.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Medifast Stock Performance

NYSE MED opened at $11.73 on Friday. The business has a fifty day moving average price of $11.75 and a 200 day moving average price of $11.35. Medifast Inc has a one year low of $9.22 and a one year high of $14.15. The company has a market cap of $131.14 million, a P/E ratio of -5.03 and a beta of 0.68.

Medifast (NYSE:MED – Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.37. The business had revenue of $76.38 million during the quarter, compared to analysts’ expectations of $72.70 million. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. As a group, sell-side analysts predict that Medifast Inc will post -1.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on MED. Zacks Research cut Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings raised Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research note on Monday, August 17th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $12.00.

Get Our Latest Analysis on Medifast

Institutional Investors Weigh In On Medifast

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MED. State of Wyoming grew its holdings in shares of Medifast by 19.8% during the 1st quarter. State of Wyoming now owns 6,646 shares of the specialty retailer’s stock worth $68,000 after purchasing an additional 1,097 shares during the period. Ancora Advisors LLC acquired a new position in Medifast in the second quarter valued at about $75,000. Quantinno Capital Management LP lifted its position in Medifast by 15.1% in the first quarter. Quantinno Capital Management LP now owns 56,153 shares of the specialty retailer’s stock valued at $572,000 after buying an additional 7,346 shares during the last quarter. Engineers Gate Manager LP boosted its stake in Medifast by 25.9% during the second quarter. Engineers Gate Manager LP now owns 49,829 shares of the specialty retailer’s stock worth $529,000 after buying an additional 10,249 shares during the period. Finally, Ieq Capital LLC purchased a new position in Medifast during the second quarter worth about $114,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

About Medifast

(Get Free Report)

Medifast, Inc (NYSE: MED) is a health and wellness company that provides weight-management and healthy-lifestyle products and programs. Its principal brand is OPTAVIA, which offers structured plans designed to support weight loss, nutrition, and long-term habit development.

The company’s product portfolio includes meal-replacement shakes, bars, snacks, entrees, beverages, supplements, and other packaged “Fuelings.” Medifast also supports customers through independent OPTAVIA Coaches, who provide guidance, accountability, and lifestyle support through the company’s direct-selling model.

Founded in 1980, Medifast serves customers primarily in the United States through its e-commerce and direct-to-consumer channels.